Medifast (NYSE:MED) Posts Better-Than-Expected Sales In Q3 But Quarterly Guidance Underwhelms

StockStory11-05

Medifast (NYSE:MED) Posts Better-Than-Expected Sales In Q3 But Quarterly Guidance Underwhelms Wellness company Medifast (NYSE:MED) reported Q3 CY2024 results exceeding the market’s revenue ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481456157?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zdquxXqvluqz4pjwDBJIkQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/add46d51010cdba90e56c97fa248b9f6","is_english":true,"pubTime":"2024-11-05 05:36","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481456157","market":"us","top_or_hot":-1,"title":"Medifast (NYSE:MED) Posts Better-Than-Expected Sales In Q3 But Quarterly Guidance Underwhelms","media":"StockStory","content":"<div>\n<p>Medifast (NYSE:MED) Posts Better-Than-Expected Sales In Q3 But Quarterly Guidance Underwhelms \n \n\nWellness company Medifast (NYSE:MED) reported Q3 CY2024 results exceeding the market’s revenue ...</p>\n\n<a href=\"https://finance.yahoo.com/news/medifast-nyse-med-posts-better-213628998.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medifast (NYSE:MED) Posts Better-Than-Expected Sales In Q3 But Quarterly Guidance Underwhelms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedifast (NYSE:MED) Posts Better-Than-Expected Sales In Q3 But Quarterly Guidance Underwhelms\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 05:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/medifast-nyse-med-posts-better-213628998.html><strong>StockStory</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Medifast (NYSE:MED) Posts Better-Than-Expected Sales In Q3 But Quarterly Guidance Underwhelms \n \n\nWellness company Medifast (NYSE:MED) reported Q3 CY2024 results exceeding the market’s revenue ...</p>\n\n<a href=\"https://finance.yahoo.com/news/medifast-nyse-med-posts-better-213628998.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MED","symbol_name":"快验保","start_time":0,"source_url":"https://finance.yahoo.com/news/medifast-nyse-med-posts-better-213628998.html","article_id":"2481456157","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zdquxXqvluqz4pjwDBJIkQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/add46d51010cdba90e56c97fa248b9f6"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481456157","pubTimestamp":1730756188,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Wellness company Medifast  reported Q3 CY2024 results exceeding the market’s revenue expectations , but sales fell 40.6% year on year to $140.2 million. On the other hand, next quarter’s revenue guidance of $110 million was less impressive, coming in 16.4% below analysts’ estimates. Its GAAP profit of $0.10 per share was also 153% above analysts’ consensus estimates.Revenue: $140.2 million vs analyst estimates of $138.2 million . “Medical innovation has transformed the weight loss industry, so at Medifast we’re creating a health and wellness business of the future by meeting the unique needs of customers regardless of their approach to their health goals,” said Dan Chard, Chairman & CEO.Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast  has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods.This quarter, Medifast’s revenue fell 40.6% year on year to $140.2 mil","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MED":"快验保","NYSE":"纽交所"},"translate_title":"快验保(NYSE：MED)第三季度销售额好于预期，但季度指引表现不佳","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MED":1,"NYSE":1},"content_text":"Medifast (NYSE:MED) Posts Better-Than-Expected Sales In Q3 But Quarterly Guidance Underwhelms \n \n\nWellness company Medifast (NYSE:MED) reported Q3 CY2024 results exceeding the market’s revenue expectations , but sales fell 40.6% year on year to $140.2 million. On the other hand, next quarter’s revenue guidance of $110 million was less impressive, coming in 16.4% below analysts’ estimates. Its GAAP profit of $0.10 per share was also 153% above analysts’ consensus estimates. \nIs now the time to buy Medifast? Find out in our full research report.\n\nMedifast (MED) Q3 CY2024 Highlights:\n\nRevenue: $140.2 million vs analyst estimates of $138.2 million (1.5% beat)\nEPS: $0.10 vs analyst estimates of -$0.19 ($0.29 beat) \nRevenue Guidance for Q4 CY2024 is $110 million at the midpoint, below analyst estimates of $131.7 million\n EPS (GAAP) guidance for Q4 CY2024 is $0.38 at the midpoint, beating analyst estimates by 368% \nGross Margin (GAAP): 75.4%, in line with the same quarter last year\nOperating Margin: 1.5%, down from 10.8% in the same quarter last year\nMarket Capitalization: $197.9 million\n\n\n“Medical innovation has transformed the weight loss industry, so at Medifast we’re creating a health and wellness business of the future by meeting the unique needs of customers regardless of their approach to their health goals,” said Dan Chard, Chairman & CEO.\nCompany Overview\nKnown for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE:MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods. \nPersonal Care\nWhile personal care products products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as \"the lipstick effect\" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering. Consumer tastes are constantly changing, and personal care companies are currently responding to the public’s increased desire for ethically produced goods by featuring natural ingredients in their products. \nSales Growth\nReviewing a company’s long-term performance can reveal insights into its business quality. Any business can have short-term success, but a top-tier one sustains growth for years. \nMedifast is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefitting from economies of scale. \n As you can see below, Medifast’s demand was weak over the last three years. Its sales fell by 21.9% annually, showing demand was weak. This is a rough starting point for our analysis. \n\nThis quarter, Medifast’s revenue fell 40.6% year on year to $140.2 million but beat Wall Street’s estimates by 1.5%. Management is currently guiding for a 42.4% year-on-year decline next quarter. \nLooking further ahead, sell-side analysts expect revenue to decline 18% over the next 12 months. While this projection is better than its three-year trend, it's tough to feel optimistic about a company facing demand difficulties. \nHere at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefitting from the rise of AI, available to you FREE via this link.\nCash Is King\nAlthough earnings are undoubtedly valuable for assessing company performance, we believe cash is king because you can’t use accounting profits to pay the bills. \nMedifast has shown robust cash profitability, driven by its attractive business model that enables it to reinvest or return capital to investors. The company’s free cash flow margin averaged 11.4% over the last two years, quite impressive for a consumer staples business. \n\nKey Takeaways from Medifast’s Q3 Results\nWe were impressed by Medifast’s optimistic EPS forecast for next quarter, which blew past analysts’ expectations. We were also excited its EPS outperformed Wall Street’s estimates. On the other hand, its revenue guidance for next quarter missed analysts’ expectations. Overall, this quarter had some key positives. The stock traded up 2.8% to $19.30 immediately after reporting. \nMedifast may have had a good quarter, but does that mean you should invest right now? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481456157"}